A Smart + Strong Site
Subscribe to:
POZ magazine
AIDS virusamdoxovir belongs to a class of anti-HIV drugs called Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIs). For a description of the life-cycle of the AIDS virus, and the targets of each class of drugs, click here.

Amdoxovir is currently being developed by RFS Pharma.

AIDS drugs chartOur quick-reference chart allows you to compare all the currently available anti-HIV drugs, including dosing, side effects, & dietary restrictions.
news Treatment News
Search for recent news and archived stories about amdoxovir.
forumsHave more questions? Then post a question or comment in our Community Forums.
Help Paying for MedsHelp Paying for Meds: Patient assistance and co-pay programs for HIV and viral hepatitis drugs.
Lessons Our Lessons: Check out our informative Lessons covering various topics to help you make treatment decisions.
Collapse All

Recommended Reading List:

Books about AIDS & HIV treatmentsFor a list of great books about living with HIV and making informed treatment decisions, along with easy links to buy them from, click here.

Amdoxovir (DAPD)


What is the most important information I should know about amdoxovir?
What is amdoxovir?
  • Amdoxovir is an anti-HIV medication. It is in a category of HIV medicines called nucleoside reverse transcriptase inhibitors (NRTIs). Amdoxovir prevents HIV from entering the nucleus of healthy T-cells. This prevents the cells from producing new virus and decreases the amount of virus in the body.
  • Amdoxovir will need to be used in combination with other drugs, including another NRTI and at least one protease inhibitor (PI) or non-nucleoside reverse transcriptase inhibitor (NNRTI).

What is already known about amdoxovir?
  • There are currently two doses of amdoxovir being studied in clinical trials: 300mg and 500mg, both of which are taken twice a day.
  • Like other NRTIs, amdoxovir might interact with other medications, including those used to treat HIV. It is important that your personal physician and/or the research nurse or study investigator be aware of all drugs you are taking, including those you buy without a prescription.
  • According to test tube studies, amdoxovir may be active against strains of the virus already resistant to other NRTIs, including Retrovir (zidovudine) and Epivir (lamivudine). However, HIV that contains a key mutation (K65R) that results in resistance to Videx (didanosine) and Viread (tenofovir) may be less sensitive to amdoxovir.
  • Amdoxovir will likely be studied and used in combination with other drugs, including another NRTI and at least one protease inhibitor or non-nucleoside reverse transcriptase inhibitor (NNRTI).
  • Amdoxovir has been tested so far in small studies, either alone or with Retrovir. Larger studies to determine the appropriate dose of amdoxovir, potential side effects and antiviral activity may are either planned or ongoing.

What about drug interactions ?
  • There is currently no information about interactions between amdoxovir and other drugs.
  • Studies on amdoxovir in combination with other drugs are ongoing.

What is known about side effects?
  • There is not a lot of information about the potential side effects of amdoxovir.
  • In animal studies, amdoxovir caused kidney and eye problems. In an early human study, kidney problems were not seen. However, five patients were required to stop the drug because of eye problems (lenticular opacities), but these problems did not appear to have any affect on vision. More studies will be needed to better understand this possible side effect. In another study, eye problems were no more likely to occur in people who took amdoxovir, compared to those who only received placebo.
  • Other side effects may occur as a result of taking amdoxovir. Further studies to determine what side effects occur most commonly with amdoxovir are either planned or ongoing.

Who should not take amdoxovir?
  • It is not known whether amdoxovir will harm an unborn baby. It is very important to treat HIV/AIDS during pregnancy to reduce the risk of infecting your baby. Talk to your doctor about your treatment options.
  • It is not known whether amdoxovir passes into breast milk and what effect it may have on a nursing baby. To prevent transmission of the virus to uninfected babies, it is recommended that HIV-positive mothers not breast-feed.

Where can I learn more about clinical trials of amdoxovir?
  • If you would like to find out if you are eligible for any clinical trials that include amdoxovir, visit, a site run by the U.S. National Institutes of Health. The site has information about all HIV-related clinical studies in the United States. For more info, you can call their toll-free number at 1-800-HIV-0440 (1-800-448-0440) or email

Last Revised: January 13, 2009

This content is written by the POZ and AIDSmeds editorial team. For more information, please visit our "About Us" page.

[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.